(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.81%) $83.17
(-1.16%) $1.619
(-0.43%) $2 337.00
(-0.04%) $27.24
(0.64%) $928.00
(-0.17%) $0.933
(-0.11%) $11.01
(-0.23%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes...
Stats | |
---|---|
本日の出来高 | 39 686.00 |
平均出来高 | 333 593 |
時価総額 | 83.28M |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -19.85 |
ATR14 | $0.00300 (1.51%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Pershing Edward | Buy | 37 752 | Series D-1 Convertible Preferred Stock |
2024-04-25 | Pershing Edward | Sell | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-19 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-11 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-06 | Pershing Edward | Buy | 47 190 | Series D-1 Convertible Preferred Stock |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 17 811 544 | Sell: 0 |
Provectus 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Provectus 財務諸表
Annual | 2023 |
収益: | $557 710 |
総利益: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
FY | 2023 |
収益: | $557 710 |
総利益: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
FY | 2022 |
収益: | $989 042 |
総利益: | $925 264 (93.55 %) |
EPS: | $-0.00850 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.0100 |
Financial Reports:
No articles found.
Provectus
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。